GCM
CNTA

Graham Capital Management’s Centessa Pharmaceuticals CNTA Stock Holding History

Graham Capital Management’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,617
Closed -$210K – 1331
2025
Q1 		$210K Buy
+14,617
New +$239K ﹤0.01% 1121

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Graham Capital Management's CNTA Position: Q2 2025 in Review

Graham Capital Management sold out of Centessa Pharmaceuticals (CNTA) in Q2 2025, closing a stake of 14,617 shares — an estimated $210K sold.

Graham Capital Management first reported a position in CNTA in Q1 2025 and held it in 1 quarter. The position peaked at $210K in Q1 2025. 117 funds tracked by Wall St. Rank hold CNTA as of Q2 2025.

  • Graham Capital Management reported no remaining Centessa Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Graham Capital Management sold 14,617 Centessa Pharmaceuticals shares in Q2 2025, an estimated $210K.
  • Graham Capital Management first reported a position in Centessa Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Graham Capital Management's Centessa Pharmaceuticals position peaked at $210K in Q1 2025.
  • 117 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2025.

Based on Graham Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.